Strategic Perspectives: Vaccines - Optimum Growth in a Crowded Market Place

Overview

Introduction

DRIVERS AND TRENDS

VACCINE POTENTIAL AND COMPLIANCE

An examination of the market potential of key current and potential vaccine disease targets, with a discussion of disease epidemiology and characterization and related social or economic issues that may have an impact on vaccine uptake.

DEVELOPMENT FOCUS

Overview of current vaccine development activity, with a comprehensive list of pipeline products, including company, brief product description and phase of development. Analysis of the pipeline is also provided by indication, vaccine type and delivery route.

VACCINE LICENSING

Many smaller biotechnology companies currently lack the capability to successfully take a product to market. Combined with the current hive of development activity, this means that there are significant opportunities for key players to in-license promising vaccines.

MANUFACTURING STRATEGIES

Vaccine companies increasingly need to develop more effective manufacturing strategies in order to compete effectively and establish best practice in this growing market. This Chapter analyzes the various advantages and disadvantages of manufacturing options currently open to vaccine companies.

DATASETS

Table 1: Number of surviving infants (000' s)

Table 2: Global vaccine sales by company, 1999-2001

Table 3: Worldwide deaths by cause and sex, 2001

Table 4: Deaths attributable to infectious diseases by region, 2001

Table 5: Annual number of surviving infants (000' s)

Table 6: Incidence of Diphtheria, Pertussis and Tetanus, 2001

Table 7: Incidence of Pneumococcal Infection in the Under 5s, 000s

Table 8: Prevalence of Chronic Hepatitis B (000s), 2001

Table 10: Pathogenic Species that Cause Otitis Media

Table 11: Prevalence of Helicobacter pylori Infection (millions), 2000

Table 12: Epidemiology of Selected Sexually Transmitted Diseases Across Seven Nations, (000s)

Table 13: Estimated cost of selected STDs in the US, 1994

Table 14: Geographical Distribution of HIV Vaccine Strains, 2001

Table 15: Patient potential for influenza vaccines in 2000, millions

Table 16: Incidence of Clostridium difficile associated Diarrhea, 2000

Table 17: Global Endemic Areas of Travelers' Infections

Table 18: Global burden of disease in disability-adjusted life years (DALYs) by cause and sex

Table 19: Burden of disease in disability-adjusted life years (DALYs) by region

Table 20: US vaccine approvals 1944-2002

Table 21: Late stage pipeline vaccines, Q4 2002

Table 22: Phase II pipeline products, Q4 2002

Table 23: Clinical trial information for selected vaccines approved by the FDA since 1996

Table 24: Ex-manufacturer sales for key vaccines, 2001-2002 ($ 000s)

Table 25: Global vaccine sales by company, 1999-2001

Table 26: GlaxoSmithKline' s marketed immunology products, 1999-2000

Table 27: GSK pipeline vaccines, Q4 2002

Table 29: Aventis Pasteur' s marketed vaccines portfolio, 2000-2001

Table 30: Aventis Pasteur' s key pipeline vaccines, 2002

Table 31: Wyeth' s marketed vaccine portfolio, 2002

Table 32: Wyeth' s key vaccine R&D pipeline, 2002

Table 34: Merck & Co.' s marketed vaccine portfolio

Table 35: Merck & Co.' s vaccine pipeline, 2002

Table 38: Chiron vaccine sales 1999-2001

Table 39: Chiron' s marketed vaccines, 2002

Table 40: Chiron' s vaccine R&D pipeline, 2002

Table 41: PowderJect' s vaccine sales, 2000-2001

Table 42: Powderject' s DNA vaccine pipeline, Q4 2002